3 days popular7 days popular1 month popular3 months popular

Gene May Help Predict Best Chemotherapy Treatment For Pancreatic Cancer Patients

Study finds patients with low RRM1 expression have better survival with gemcitabine Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States. Researcher Richard Kim, M.D., assistant member of the Experimental Therapeutics Program and colleagues from several other [...]

Abraxane® (Nab-Paclitaxel) Plus Gemcitabine Demonstrates Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer

Nab-paclitaxel plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups1 Oral Presentation Scheduled for Friday, January 25th at ASCO’s Gastrointestinal Cancers Symposium Annual Meeting Celgene UK and Ireland, a subsidiary of Celgene Corporation (NASDAQ: CELG), have announced that its phase III [...]

Harnessing Anticancer Drugs For The Future Fight Against Influenza

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs. The researchers were able to identify two novel compounds with anti-influenza activity, obatoclax and gemcitabine and [...]

First Patient Enrolled In A Clinical Study With CP-4126 In Combination With Cisplatin In Non-Small Cell Lung Cancer

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that a Phase I study of CP-4126 (CO-101) in combination with cisplatin in non-small-cell lung cancer (NSCLC) has been initiated by its partner Clovis Oncology. The first patient has now been dosed in this two-part study, which is being conducted at cancer centres [...]